J.D. Spicer

LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC

Tina Cascone, Mark M. Awad, J.D. Spicer et al. · Annals of Oncology · 2023 · 100 citations · Full text

Surgical Oncology, Medicine, Pharmacology +8

LBA56 Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)

J.D. Spicer, Shugeng Gao, Moïshe Liberman et al. · Annals of Oncology · 2023 · 70 citations · Full text

Keynote-671 Study, Perioperative Pembrolizumab, Medicine +7

LBA57 Neoadjuvant nivolumab (N) + chemotherapy (C) in the phase III CheckMate 816 study: 3-y results by tumor PD-L1 expression

Mariano Provencio, Patrick M. Forde, J.D. Spicer et al. · Annals of Oncology · 2023 · 18 citations · Full text

Lba57 Neoadjuvant Nivolumab, Oncology, Medicine +9

1261O Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase III CheckMate 816 trial

Mark M. Awad, Patrick M. Forde, Nicolas Girard et al. · Annals of Oncology · 2023 · 17 citations · Full text

Oncology, Pharmacology, Clinical Trials +7

LBA50 Perioperative nivolumab (NIVO) v placebo (PBO) in patients (pts) with resectable NSCLC: Clinical update from the phase III CheckMate 77T study

Mariano Provencio, Mark M. Awad, Tina Cascone et al. · Annals of Oncology · 2024 · 16 citations · Full text

Oncology, Medicine, V Placebo +8